Gene therapy and special goggles help some blind adults detect objects again

https://www.news-medical.net/news/20261012/Gene-therapy-and-special-goggles-help-some-blind-adults-detect-objects-again.aspx Scientists are testing whether surviving retinal nerve cells, a light-sensitive protein, and specially designed goggles could offer a new way to process visual information after severe vision loss. A recent New England Journal of Medicine study evaluated the safety and preliminary visual-function outcomes of optogenetic therapy in adults with advanced retinitis pigmentosa.

Beyond ‘bad’ cholesterol: new clues to the risk of heart disease

https://www.news-medical.net/news/20261013/Beyond-e28098bade28099-cholesterol-new-clues-to-the-risk-of-heart-disease.aspx Researchers at Chalmers University of Technology, in Sweden, shed new light on the remaining risk of heart disease, even after the known risk factor of ‘bad’ cholesterol is brought down to a healthy level. In a new study, key biological pathways – and an understanding of how the body is affected – were identified for the particles believed to contribute to the remaining disease risk. The results pave the way for more closely targeted prevention in heart disease which ultimately may save more lives.

Leech Therapy: How It Works and Its Uses in Modern Medicine

https://www.news-medical.net/health/Leech-Therapy-How-It-Works-and-Its-Uses-in-Modern-Medicine.aspx Once prized for bloodletting, medicinal leeches are drawing fresh scientific interest for the complex molecular pharmacy hidden in their saliva. Leeches have been used for thousands of years for bloodletting, which was thought to cure various illnesses. Modern medicine and drug discovery have rekindled interest in the pharmacologically active molecules found in leech saliva. Proteomic and transcriptomic studies have identified more than 100 salivary proteins and peptides, but only a fraction have been functionally characterized, and few have advanced into pharmaceutical development.2,3

Eye Microbiome: How Bacteria May Influence Eye Health and Disease

https://www.news-medical.net/health/Eye-Microbiome-How-Bacteria-May-Influence-Eye-Health-and-Disease.aspx The eye's surface hosts a low-abundance microbial community, while the possible existence of a resident microbiome inside the eye remains under investigation. Previously, the intraocular environment was considered sterile, while culture-based studies had long identified microorganisms on the ocular surface. Reports of microbial genetic material in intraocular samples have raised questions about possible resident organisms, but their presence and significance remain uncertain.3 More recent molecular techniques, such as 16S ribosomal ribonucleic acid (rRNA) gene sequencing and whole-metagenome shotgun sequencing, have expanded our understanding of the ocular microbiome. The 16S method primarily profiles bacteria, while shotgun sequencing can also detect DNA from fungi, DNA viruses, and other microorganisms.1 The ocular surface contains low microbial biomass and is highly susceptible to contamination from surrounding tissues and the environment.

Patients Turn to GPs to Chase Care Elsewhere in the NHS Rob Hicks, MBBS

https://www.medscape.com/viewarticle/patients-turn-gps-chase-care-elsewhere-nhs-2026a100129s More than 4 in 5 UK adults have at times been unsure who to contact in the NHS about their care, according to a survey conducted for the Royal College of General Practitioners (RCGP), which says patients are struggling to navigate a “maze” of referrals, appointments, and follow-ups.

Scalding Drinks Increase Esophageal Cancer Risk Benjamin H. Levy, III, MD; Emil Lou, MD, PhD

https://www.medscape.com/viewarticle/scalding-drinks-increase-esophageal-cancer-risk-2026a100118p?src=

ctDNA-Guided Chemo Shows Promise in Stage II Colorectal Cancer David Kerr, MD, DSc

https://www.medscape.com/viewarticle/ctdna-guided-chemo-shows-promise-stage-ii-colorectal-cancer-2026a10010tf?src=

Chemo- or Surgery-First in Advanced Gastric Cancer?

https://www.medscape.com/viewarticle/chemo-or-surgery-first-advanced-gastric-cancer-2026a10011tu?src= Patients with gastric cancer and positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) who received upfront chemotherapy followed by gastrectomy had a higher 5-year overall survival rate than those who underwent upfront gastrectomy followed by postoperative chemotherapy. Survival was highest among patients who achieved conversion to no peritoneal metastasis and negative cytology (P0CY0) before gastrectomy, with a 5-year overall survival rate of about 50%.

KADCYLA is the first and only targeted treatment option in residual invasive HER2+ eBC, supported by 7 years of OS data

https://global.phesgo-hcp.com/kadcyla-residual-invasive.html?cid=na4847551127&utm_source=medscape&utm_medium=na&utm_campaign=her2_2026&utm_content=tx%3Akadcylanc1%3A2609%3Axx&dclid=CjgKEAjwrbfWBhCKtsPFysPgzWkSJACg-Z-IqsDZKANghFA-OccZm_nf9UsMt-DwfS1lNwIfnCdERvD_BwE&gad_source=7

RNA Test Shows Promise for Guiding Bladder Cancer Treatment Lisa O’Mary

https://www.medscape.com/viewarticle/rna-test-shows-promise-guiding-bladder-cancer-treatment-2026a10012c2?src= A new urine cell-free RNA (cfRNA) test for bladder cancer shows promise as a functional liquid biopsy to guide treatment decisions regarding the use of the first-line immunotherapy Bacillus Calmette-Guérin (BCG).

Sentinel Node Biopsy May Aid Staging in Locally Advanced Breast Cancer

https://www.medscape.com/viewarticle/sentinel-node-biopsy-may-aid-staging-locally-advanced-breast-2026a100120s?src= Sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy identified at least one sentinel lymph node in 74% of patients with locally advanced breast cancer who became clinically node negative. Among patients with adequate mapping and residual nodal disease, the false-negative rate was 2.1%. The findings suggest SLNB may help assess axillary disease after neoadjuvant chemotherapy in selected patients, but do not establish that it can safely replace axillary lymph node dissection.

Dogs, Devils, Clams, and Catfish: When Cancer Is Contagious Nala Rogers

https://www.medscape.com/s/viewarticle/dogs-devils-clams-and-catfish-when-cancer-contagious-2026a10012a5?src= Human beings — at least for now — have just one world. And the same is true for most cancers, trapped as they are in the body from which they arose and multiplying until their resources run out. Then, says Joel Brown, an evolutionary ecologist at the Moffitt Cancer Center in Tampa, Florida, “they die with their planet.”

When and How Can Functional Somatic Disorders Be Treated? Jean-Bernard Gervais

https://www.medscape.com/viewarticle/when-and-how-can-functional-somatic-disorders-be-treated-2026a10012b8?src= Functional somatic disorders (FSDs) are characterized by persistent physical symptoms that cannot be fully explained by identifiable organic abnormalities. They account for 30%-40% of consultations across medical specialties and can substantially disrupt patients’ lives. During the 2026 National Days of General Medicine (JNMG), held on September 24-25 in Paris, France, Brigitte Ranque, MD, PhD, professor and head, Department of Internal Medicine, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP); medical lead, CASPER Unit, Hôtel-Dieu, AP-HP; and professor, Université Paris Cité, Paris, France, discussed how to recognize and manage these disorders.

Age-Based Testing Misses Most With Inherited Cancer Risk Frederik Joelving

https://www.medscape.com/viewarticle/age-based-testing-misses-most-inherited-cancer-risk-2026a10012ct?src= Restricting germline genetic testing to patients diagnosed with cancer before age 50 may miss the large majority of all those with inherited pathogenic variants, a new study suggested.

Do Sugary Drinks Increase Cancer Risk? It’s Complicated David Brzostowicki

https://www.medscape.com/viewarticle/do-sugary-drinks-increase-cancer-risk-its-complicated-2026a100123m A recent study adds to a growing, but mixed, body of evidence examining whether sugar-sweetened beverages and other sources of sugar are associated with risk for cancer. The study, published in Gastro Hep Advances, found that US nurses and other health professionals who drank more than one sugar-sweetened beverage a day had a nearly 2.5 fold higher incidence of gastric cancer than those who essentially steered clear.

Don’t Wait to Act: Recognizing Refractory HSV and Leveraging New Treatment Pathways Authors: Anum Abbas, MD; Jonathan M. Hand, MD

https://www.medscape.org/viewarticle/dont-wait-act-recognizing-refractory-hsv-and-leveraging-new-2026a10010ym?page=1

Beyond PD-L1: Personalizing Immunotherapy in Genomic Subsets of Advanced NSCLC Authors: Fred R. Hirsch, MD, PhD, FASCO; Ana Baramidze, MD, PhD

https://www.medscape.org/viewarticle/beyond-pd-l1-personalizing-immunotherapy-genomic-subsets-2026a10010bq?page=1

Frontiers in Modern Oncology: Molecular-Guided Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer Authors: Giuseppe Curigliano, MD, PhD; Nicola Fusco, M

https://www.medscape.org/viewarticle/frontiers-modern-oncology-molecular-guided-strategies-hr-2026a10010ph?page=1

Navigating Next Steps in CLL: A Collaborative Dialogue Authors: Chaitra Ujjani, MD

https://www.medscape.org/viewarticle/navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d?page=1&src=mkmcmr_driv_stan_mscpedu_261012-OUS-HONC-navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d-cta&uac=148436CN

Including women in clinical trials isn’t enough Thirty years after women were formally brought into clinical research, inclusion has improved but important questions remain about how sex, pregnancy, and menopause affect drug safety and efficacy. Written byBree Foster, PhD

Including women in clinical trials isn’t enough Thirty years after women were formally brought into clinical research, inclusion has improved but important questions remain about how sex, pregnancy, and menopause affect drug safety and efficacy. Written byBree Foster, PhD https://www.drugdiscoverynews.com/including-women-in-clinical-trials-isn-t-enough-17547?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-987umcgyZyybU1C6LRPXLrtpT14yVtKeK7Ii0Yq1kujW0McI7IV9FDTHmaQGuxd4Ie9niFifIvL8Tm3S9q0ODxBn7xBw&_hsmi=443497174&utm_content=443497174&utm_source=hs_email Despite making up almost half of the world’s population, women have historically been underrepresented in clinical studies. It was only in 1993 that the NIH Revitalization Act established that women and minorities had to be included in all NIH-funded clinical research. That same year, the FDA issued guidance encouraging the inclusion of women in clinical trials, including early-phase studies. This legacy of exclusion has left critical gaps in our understanding of how diseases and treatments affect women, with potential consequences for drug safety and efficacy.

White Papers (+++)

Advancing biological imaging with submicron IR Biological analysis is dealing with a persistent gap in understanding: the tools used to reveal molecular chemistry rarely resolve it in space. For example, though infrared spectroscopy can identify functional defects without labels, its diffraction is limited to several micrometers, which is too coarse for subcellular detail. Raman spectroscopy, unlike infrared, reaches sub-micrometer resolution but is hindered by weak signals and fluorescence backgrounds in biological specimens. https://www.news-medical.net/whitepaper/20261012/Advancing-biological-imaging-with-submicron-IR.aspx Tracking lipid metabolism with submicron IR It is well documented that saturated fatty acids are more toxic than unsaturated ones. However, the underlying mechanism remains unresolved because it is extremely difficult to visualize the subcellular chemical conversions at the root of lipotoxicity, the lipid accumulation that leads to cell death and metabolic diseases such as MASLD, in living cells. For researchers investigating lipid metabolism and liver disease, it is vital to make the connection between fatty acid chemistry and specific organelles. To better understand this long-standing research gap, researchers at Yale University have set out to investigate how saturated palmitic acid (PA) drives lipotoxicity. https://www.news-medical.net/whitepaper/20261009/Tracking-lipid-metabolism-with-submicron-IR.aspx Microfluidics is transforming early-stage nanoparticle formulation for drug delivery The rapid evolution of nanomedicine has elevated drug delivery from a formulation challenge to a critical factor determining therapeutic success. Whether developing mRNA vaccines, cancer therapeutics, or targeted gene therapies, researchers must balance particle size, encapsulation efficiency, and reproducibility, all while accelerating development timelines. Microfluidic technologies are emerging as a powerful solution to these challenges. By enabling precise control over nanoparticle formation, they offer researchers a faster and more reproducible alternative to conventional formulation methods. Combined with ready-to-use formulation kits, these platforms are making sophisticated nanoparticle development more accessible for laboratories across academia and industry. https://www.news-medical.net/whitepaper/20261009/Microfluidics-is-transforming-drug-delivery-from-discovery-to-scalable-manufacturing.aspx

Health Articles (+++)

Improving cell recovery and growth with macromolecular crowding This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment. https://www.news-medical.net/health/Improving-cell-recovery-and-growth-with-macromolecular-crowding.aspx Translating organoid research into drug discovery insights This article and associated images are based on a poster originally authored by Fazel Gorjipour, Mehdi Kazemzadeh-Narbat, Hesam Ghiasvand, and Şerif Şentürk and presented at ELRIG Drug Discovery 2026 in affiliation with İzmir Biomedicine and Genome Center, MCRA LLC, Coventry University, and Dokuz Eylül University. https://www.news-medical.net/health/Translating-organoid-research-into-drug-discovery-insights.aspx Using live-cell fluorescence to assess SOD1 A4V aggregation in ALS This article and associated images are based on a poster originally authored by C. Salado, R. M. Mella, M. Roura-Ferrer, E. Hernández-Imaz, and P. Villacé and presented at ELRIG Drug Discovery 2026 in affiliation with Innoprot. This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment. https://www.news-medical.net/health/Using-live-cell-fluorescence-to-assess-SOD1-A4V-aggregation-in-ALS.aspx

Women with bipolar disorder and regular cycles report worse premenstrual symptoms

https://www.news-medical.net/news/20261011/Women-with-bipolar-disorder-and-regular-cycles-report-worse-premenstrual-symptoms.aspx Researchers have found that women with bipolar disorder who have regular menstrual cycles are more likely to report severe premenstrual symptoms than those with irregular cycles, according to preliminary research being presented at the 2026 ECNP Congress in Munich.

Severe long Covid associated with distinct oral and lung microbiomes

https://www.news-medical.net/news/20261011/Severe-long-Covid-associated-with-distinct-oral-and-lung-microbiomes.aspx A study of more than 700 people has shown that those with long Covid have distinct differences in the mix of bacteria that live in their mouths and lungs, according to a study published today (Monday) in the European Respiratory Journal. The research also shows that these differences in the lung microbiome are linked to respiratory symptoms, as well as the cognitive and digestive problems known to occur in long Covid. Researchers say their findings may shed light on why some people develop long Covid and they could point to new ways to treat the condition.

Diet drinks showed no clear weight-loss edge over water after two years

https://www.news-medical.net/news/20261011/Diet-drinks-showed-no-clear-weight-loss-edge-over-water-after-two-years.aspx After structured support ended, researchers tracked weight regain, hunger, and metabolic changes to examine how daily beverage choices fit into long-term weight management. A recent randomized controlled trial (RCT) published in the British Journal of Nutrition found that participants who drank water or non-nutritive sweetened (NNS) beverages and participated in weight management programs lost weight and maintained some of that loss for two years. Based on the observations, NNS beverages could offer a flavored option alongside water during structured weight management, but the trial directly compared these beverages with water and did not establish cardiometabolic benefits.

Study reveals continued care delays among patients with young-onset breast cancer

https://www.news-medical.net/news/20261012/Study-reveals-continued-care-delays-among-patients-with-young-onset-breast-cancer.aspx In an analysis of data on adolescents and young adults with breast cancer, lower income and younger age were linked with delays in care. The analysis published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, also found that women who experienced delays in cancer diagnoses tended to have later stages of disease.

New research links water source type to antibiotic resistance

https://www.news-medical.net/news/20261012/New-research-links-water-source-type-to-antibiotic-resistance.aspx Aquatic environments are recognized as reservoirs and pathways for antimicrobial resistance, receiving antibiotic residues and resistant microorganisms from sewage, livestock farming, and aquaculture. Previous studies have detected resistance genes in drinking water sources and shown that conventional treatment may remove them incompletely. However, monitoring often focuses on individual pollutants or limited locations, leaving the relationships between antibiotic contamination, resistance genes, and bacterial resistance poorly understood. Rivers, enclosed reservoirs, and open lakes also differ in pollution exposure and water movement. In the Poyang Lake basin, which supplies drinking water sources for approximately 45 million people, a comprehensive comparison was needed to identify priority locations and factors associated with resistance.

Study reveals how different plant saponins alleviate ischemic stroke

https://www.news-medical.net/news/20261012/Study-reveals-how-different-plant-saponins-alleviate-ischemic-stroke.aspx Ischemic stroke accounts for approximately 85% of all strokes and remains a major cause of death and long-term disability. Current treatments can restore blood flow in eligible patients, but therapeutic options remain limited, particularly for protecting threatened brain tissue and supporting recovery. P. notoginseng and P. ginseng have long been used in traditional Chinese medicine and are commonly associated with "activating blood" and "replenishing qi," respectively. Modern studies have reported anti-inflammatory, antioxidant, and anti-apoptotic effects for their saponins. However, conventional bulk and single-cell analyses cannot fully show where drug-induced molecular changes occur within the spatially heterogeneous brain, leaving the regional differences between these treatments insufficiently understood.

Think raw milk is better for you? Pediatricians have a warning

https://www.news-medical.net/news/20261012/Think-raw-milk-is-better-for-you-Pediatricians-have-a-warning.aspx With hundreds of illnesses linked to raw milk outbreaks and emerging concerns over bird flu, pediatricians warn that unpasteurized dairy poses preventable health risks without delivering the nutritional benefits its supporters claim. A recent policy statement from the American Academy of Pediatrics (AAP), published in Pediatrics, concluded that raw milk offers no proven health advantages over pasteurized milk that outweigh its increased risk of foodborne illness.

Med Op-Ed: Supplements, Costs, and Value in Cancer Care Edited by Victoria Stern

https://www.medscape.com/viewarticle/med-op-ed-supplements-costs-and-value-cancer-care-2026a10011ox?ecd=WNL_trdalrt_pos1_ous_261012_etid8786199&uac=148436CN&impID=8786199 In this installment of Med Op-Ed: What should patients know about supplements during cancer treatment? How can oncologists approach conversations about the costs of care? And is cancer care being valued and reimbursed appropriately?

The latest edition of RARE Revolution Magazine has dropped—The RARE-linked edition is now LIVE!

https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=a879f992-d7b6-4577-a1e2-3ba26643b60c The community turning the tide for RARE and X-linked disorders The Autumn 2026 edition of RARE Revolution Magazine (Issue 037) has landed! This edition focuses on X-linked genetic disorders, a category encompassing over 500 conditions linked to variants on the X chromosome. The edition highlights a pivotal shift across the rare disease ecosystem—contrasting the challenges of diagnostic odysseys, insurance coverage battles and adult transition gaps with groundbreaking progress in targeted therapies, parent-led translational research and global community building. Above all, it celebrates the extraordinary strength and everyday joy found within rare disease families. Featuring: Great expectations: reframing life with Renpenning syndrome – An interview with rare parent and advocate Jessica Nunley on releasing preconceived expectations, navigating early intervention, and advocating for her son Gryffin. 60 years of fast-paced progress in Rett syndrome – Professor Dimitrios I. Zafeiriou reflects on six decades of evolution in Rett syndrome care, moving from basic symptom management to targeted treatments and gene therapy trials. The heart, soul, and glue of Wiskott-Aldrich syndrome – The story of how Mike Skrynecki and Dr Sumathi Iyengar co-founded the Wiskott-Aldrich Foundation, rescued an almost-abandoned gene therapy programme and reshaped global care standards. Living on a "cliff edge": fragile X and the fight for Austin’s future – Georgina Fane shares the realities of raising her 17-year-old son Austin and the looming systemic battle surrounding transition into adult care services. Plus so much more, including – Menkes disease, CASK, Barth syndrome, XLP1, XLA, Fabry disease, Aicardi syndrome and much more. You can view this publication from a desktop, laptop, mobile or tablet and it is packed with interactive links so you can enjoy the best possible experience when engaging with the content. And don't forget you can also view from our website at any time, along with lots of other great digital content. www.rarerevolutionmagazine.com https://rarerevolutionmagazine.com/

The Next Frontier in Metastatic CRPC: The EZH2 Pathway and Emerging Therapies Authors: Elena Castro, MD, PhD; Michael Schweizer, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq?page=1&src=mkmcmr_driv_stan_mscpedu_261009-OUS-HONC-next-frontier-metastatic-crpc-ezh2-pathway-and-emerging-2026a10009uq-cta&uac=148436CN

Pancreatic Cancer Therapy Rates Diverge Sharply in US, Dutch Data Megan Brooks

https://www.medscape.com/viewarticle/pancreatic-cancer-therapy-rates-diverge-sharply-us-dutch-2026a10011iq?ecd=WNL_trdalrt_pos1_ous_261009_etid8776881&uac=148436CN&impID=8776881 Two large real-world studies of patients with metastatic pancreatic cancer — one from Netherlands and one from the US — paint strikingly different pictures of systemic therapy use. A nationwide Dutch study reported that nearly three quarters of patients with metastatic pancreatic cancer did not receive systemic therapy, whereas a contemporary US cohort study found that only one third did not receive treatment.

Rethinking lived experience The Lancet (++... +)

Rethinking lived experience The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02038-6/fulltext?dgcid=raven_jbs_etoc_email The theme of this year's World Mental Health Day, held on Oct 10, is Lived experiences heard: real voices, real change. On its website, WHO states that the voices of people with lived experience should “shape the policies, services and decisions that affect their lives”. While these are laudable aims, they also serve to highlight the complex challenges involved in lived experience engagement and co-production, both within the field of mental health and beyond. Oct 10, 2026 Volume 408Number 10563p1397-1524 https://www.thelancet.com/journals/lancet/issue/vol408no10563/PIIS0140-6736(26)X2038-4 Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Virginia Bellido, PhDa Send email to virginiabellido@gmail.com ∙ Carel W le Roux, PhDb,c ∙ Elif I Ekinci, PhDd,e ∙ Petter Bjornstad, MDf ∙ Juan P Frias, MDg ∙ Kathryn Giblin, MDh ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01861-1/abstract?dgcid=raven_jbs_etoc_feature_lancet

Meet the neurosurgeon-CEO taking on cancer drug resistance John Yu built Kairos Pharma on a simple bet: Cancer drugs don't fail, tumors just learn to outrun them. Written byAndrea Corona

Meet the neurosurgeon-CEO taking on cancer drug resistance John Yu built Kairos Pharma on a simple bet: Cancer drugs don't fail, tumors just learn to outrun them. Written byAndrea Corona https://www.drugdiscoverynews.com/meet-the-neurosurgeon-ceo-taking-on-cancer-drug-resistance-17566?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_NtXt8hiu2vj7MAkNXnqrLjZ6tpef8z7jlSl5-7rHf9G5ZCW6xlDqcBdYJIierg0SK-B_y9ylMNqsoMBe0BwFqj9Hv0A&_hsmi=443509489&utm_content=443509487&utm_source=hs_email DDN caught up with John Yu, the Kairos Pharma CEO about the mechanism his company is betting on and how he splits his time between the operating room and the bench. A neurosurgeon at Cedars-Sinai Medical Center who still runs an NIH-funded lab there, Yu founded Kairos Pharma to chase a problem he kept seeing in his own patients: a cancer drug works well for months, sometimes a couple of years, and then the tumor comes back anyway.

Charting New Frontiers in Advanced Breast Cancer: Milestones, Missions, and Mastery Authors: Paolo Tarantino, MD, PhD; Kevin Kalinsky, MD, MS, FASCO; Sibylle Loibl, MD, PhD

https://www.medscape.org/viewarticle/charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7?page=1&src=mkmcmr_driv_stan_mscpedu_261011-OUS-HONC-charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7-cta&uac=148436CN

Advancing Care in HER2-Mutated NSCLC: Evidence, Diagnostics, and Future Directions Authors: Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g?page=1&src=mkmcmr_driv_stan_mscpedu_261011-OUS-HONC-advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g-cta&uac=148436CN

Lessons From the Real World: Treating High Risk HR+/HER2- Breast Cancer According to the Latest Evidence Authors: Nadia Harbeck, MD, PhD; Stephen Johnston, MA, FRCP, PhD; Sara Tolaney, MD, PhD

https://www.medscape.org/viewarticle/lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd?page=1&src=mkmcmr_driv_stan_mscpedu_261012-OUS-HONC-lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd-cta&uac=148436CN

Ewing sarcoma and paediatric cancer burden: we need more robust registries The Lancet Regional Health – Americas (+ +... ++)

Ewing sarcoma and paediatric cancer burden: we need more robust registries The Lancet Regional Health – Americas https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00313-3/fulltext?dgcid=raven_jbs_etoc_email Since 2007, at least nine unrelated children from Ladera Ranch, a small community in Orange County, Southern CA, USA, have been diagnosed with Ewing sarcoma, a very rare tumour of bone and surrounding soft tissues that mainly affects children and young adults. If the tumour has not spread, the 5-year survival is nearly 75%. The report of a substantial number of Ewing sarcoma cases within a small area, considering the rarity of the disease (an annual incidence of nearly three cases per million people in the USA), has left community members, patients and families, and experts with many unanswered questions. Concerns have been raised that possible environmental factors may be involved. However, as it is the case for most childhood cancers, Ewing sarcoma does not yet have an established cause. Oct 2026 Volume 62 https://www.thelancet.com/journals/lanam/issue/vol62nonull/PIIS2667-193X(26)X2007-5 Ultra-processed food intake and risk of renal cell carcinoma in the NIH-AARP Diet and health study: a prospective cohort analysis Kaelyn F. Burnsa Send email to kaelyn.burns@nih.gov ∙ Mark P. Purdueb ∙ Neha Khandpurc ∙ Euridice Martinez-Steeled,e ∙ Rashmi Sinhaa ∙ Hyokyoung G. Hongf ∙ et al. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00178-X/fulltext?dgcid=raven_jbs_etoc_feature_lanam Ultra-processed foods (UPF) are widely consumed and have been linked to obesity and hypertension, risk factors of renal cell carcinoma (RCC) and the common clear cell (cc) RCC subtype. We evaluated the association between UPF and RCC. The burden of noncommunicable and injury-related nervous system disorders in the Americas, 1990–2023: an analysis of the Global Burden of Disease Study 2023 Ramon Martineza Send email to martiner@paho.org ∙ Kiran T. Thakurb ∙ Luisa F. Alvizb ∙ William M. Gardnerb ∙ Francisco J. Varelac ∙ Anselm J.M. Hennisa ∙ et al. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00211-5/fulltext?dgcid=raven_jbs_etoc_feature_lanam Noncommunicable and injury-related nervous system disorders (NINSDs)—including cerebrovascular and neurodegenerative diseases, neurodevelopmental disorders, neuromuscular conditions, brain cancers, and traumatic brain injuries—are major contributors to morbidity, disability, and premature mortality in the Americas. However, comprehensive regional and national assessments remain limited. We assessed the burden of NINSDs and their attributable risk factors in the Americas from 1990 to 2023.

Children with arthritis: orphans of the NCD agenda? The Lancet Glob Health (+ +... ++)

Children with arthritis: orphans of the NCD agenda? The Lancet Glob Health https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00272-X/fulltext?dgcid=raven_jbs_etoc_email Musculoskeletal conditions, including forms of inflammatory arthritis such as juvenile idiopathic arthritis, rheumatoid arthritis, and axial spondyloarthritis, are leading causes of disability-adjusted life-years globally. In 2020, 17·6 million people were estimated to have rheumatoid arthritis, and juvenile idiopathic arthritis affected more than 2 million children worldwide. These conditions present a substantial threat to healthy ageing, causing chronic pain, limiting mobility and reducing participation in education and employment. World Arthritis Day (October 12) is an opportunity to draw attention to these under-recognised non-communicable diseases (NCDs), particularly among children in low-income and middle-income countries (LMICs). Oct 2026 Volume 14Number 10 https://www.thelancet.com/journals/langlo/issue/vol14no10/PIIS2214-109X(26)X2008-3 Beyond monitoring misery during conflict: the political economy of global health reform Adam P Coutts, PhDa,f Send email to apc31@cam.ac.uk ∙ Miriam Orcutt, MBBS MScb,g ∙ Richard Sullivan, FRCS PhDc ∙ Abdulkarim Ekzayez, MD PhDd ∙ Vlad Chaddad, MD https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00200-7/fulltext?dgcid=raven_jbs_etoc_feature_langlo Global health researchers, UN agencies, and donors have become expert at documenting the deterioration of population health during conflict, yet documentation has not stopped that deterioration. Drawing on 15 years of field research in Syria, Lebanon, Gaza, and Jordan, we argue that part of the failure of the global health architecture stems not principally from violations of international humanitarian law, but from its design as a technical enterprise detached from the political economy of power, financing, and governance. In practice, the system was structured to document harm rather than to hold anyone accountable for it. We distinguish humanitarian neutrality, understood as the operational duty to assist all civilians, from technical neutrality, which excludes political accountability in ways that protects institutional relationships and funding. We define a political economy of health approach, identify specific actors capable of changing the system, and acknowledge both the real, although uneven, effects of documentation and the structural constraints, namely sovereignty, donor dependence, and entrenched interests, that any reform should confront. Finally, we propose six concrete shifts to move global health from monitoring harm and misery towards enabling accountability. Drivers of adolescent pregnancy decline in five adolescent sexual and reproductive health and rights exemplar countries: a quantitative decomposition analysis Corinne Bintz Aerenson, MSa ∙ Olivia Angelino, MPHa ∙ Michael Give Chipeta, PhDb ∙ Naa Dodua Dodoo, PhDb ∙ Prof Erigene Rutayisire, PhDc ∙ Jean Christophe Fotso, PhDd ∙ et al. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00196-8/fulltext?dgcid=raven_jbs_etoc_feature_langlo

Bipolar Disorder and Parkinson’s Disease: Which Comes First? Dawn Attride

https://www.medscape.com/viewarticle/bipolar-disorder-and-parkinsons-disease-which-comes-first-2026a10011wn?ecd=wnl_tp10_daily_261010_MSCPEDIT_etid8777746&uac=148436CN&impID=8777746

Coffee's Hidden Effects on Gut Health Edited by Medscape Staff

https://www.medscape.com/s/viewarticle/coffees-hidden-effects-gut-health-2026a10011my?ecd=wnl_tp10_daily_261010_MSCPEDIT_etid8777746&uac=148436CN&impID=8777746

ECG Challenge: Changing Heart Rhythm on the Way to the Cath Lab Philip J. Podrid, MD

https://www.medscape.com/viewarticle/ecg-challenge-changing-heart-rhythm-way-cath-lab-2026a1000nci?ecd=mkm_ret_261010_mscpmrk_cardio_ECG-challenge_etid8777987&uac=148436CN&impID=8777987

From Resection to Dose Individualized Antigen-Directed Therapeutics in Immuno-Oncology CME Phoenix Convention Center Saturday, November 7, 2026 | 12:30 pm - 1:30 pm MST

https://na.eventscloud.com/website/100106/ Messenger RNA (mRNA)-based therapeutics have moved from concept into clinical evaluation across immuno-oncology. This symposium discusses how mRNA-encoded, antigen-directed approaches generate anti-tumor immunity, and how they sit alongside checkpoint inhibition, cell therapy and other novel modalities. Faculty will cover the mechanistic basis of mRNA therapies — antigen selection and prediction, delivery, and the resulting T-cell priming and expansion — and how this differs from other immunotherapeutic approaches. The program will review current clinical evidence across tumor types and disease settings, including earlier-stage and minimal residual disease contexts, matching the strength of each conclusion to the design that produced it. Sessions will also address biomarker and patient-selection considerations, including tumor mutational burden, neoantigen burden and circulating tumor DNA (ctDNA)-based measures, and the multidisciplinary requirements of delivering individualized therapies in practice. The From Resection to Dose: Individualized Antigen-Directed Therapeutics in Immuno-Oncology, content and views expressed therein are those of Medscape Education and not of SITC.

Fast Five Quiz: Interstitial Lung Disease and Nonidiopathic Pulmonary Fibrosis Zab Mosenifar, MD (++)

Fast Five Quiz: Interstitial Lung Disease and Nonidiopathic Pulmonary Fibrosis Zab Mosenifar, MD https://reference.medscape.com/viewarticle/fast-five-quiz-interstitial-lung-disease-and-nonidiopathic-2026a1000z4v?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 Nonidiopathic pulmonary fibrosis interstitial lung diseases (ILDs) are fibrotic lung disorders linked to identifiable causes, including autoimmune disease, environmental or occupational exposures, medications, and other underlying conditions. Although they can share radiographic and physiologic features, their course, prognosis, and management may differ substantially. Regular reassessment for clinical, physiologic, and radiologic progression is therefore essential. Rapid Review Quiz: Respiratory Syncytial Virus in Adults Zab Mosenifar, MD https://reference.medscape.com/viewarticle/rapid-review-quiz-respiratory-syncytial-virus-adults-2026a1000xpr?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 Respiratory syncytial virus (RSV) is primarily spread through respiratory droplets, either by direct contact with an infected person or by touching contaminated surfaces. Clinical features may be difficult to differentiate from those of other respiratory viral infections; as a result, diagnosis can be delayed, affecting clinical management and outcomes.

The 90-Day CPAP Cutoff May Be Too Soon to Measure Success Edited by Medscape Staff (++)

https://www.medscape.com/s/viewarticle/90-day-cpap-cutoff-may-be-too-soon-measure-success-2026a1000yh4?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 Balloon Dilation Fills Gap for Granulomatosis With Polyangiitis Care Heidi Splete https://www.medscape.com/viewarticle/balloon-dilation-fills-gap-granulomatosis-polyangiitis-care-2026a1000z94?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820

Moving Beyond Syndromic Rescue to Precision Targeting of Viral Triggers, Airway Inflammation in COPD (+++)

Moving Beyond Syndromic Rescue to Precision Targeting of Viral Triggers, Airway Inflammation in COPD https://www.medscape.com/viewarticle/moving-beyond-syndromic-rescue-precision-targeting-viral-2026a1000zeg?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 BARCELONA, Spain — Managing an acute viral flare-up of chronic obstructive pulmonary disease (COPD) involves prescribing a course of oral corticosteroids, broad-spectrum antibiotics, and hoping the patient’s lungs recover. But experts at the European Respiratory Society (ERS) 2026 International Congress argued that this nonspecific, syndromic rescue model is ineffective. Respiratory viruses trigger roughly half of all COPD exacerbations, and even a single moderate event permanently alters a patient’s survival trajectory while accelerating lung function decline. Tozorakimab Cuts COPD Exacerbations by Up to 34% in Phase 3 Trials Manuela Callari https://www.medscape.com/viewarticle/tozorakimab-cuts-copd-exacerbations-34-phase-3-trials-2026a10010g0?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 BARCELONA, Spain — Add-on treatment with tozorakimab, a first-in-class monoclonal antibody targeting interleukin-33 (IL-33), significantly reduces the yearly rate of moderate and severe COPD exacerbations in patients receiving stable standard-of-care inhaled maintenance therapy. European Respiratory Society (ERS) 2026 International Congress https://www.medscape.com/c25/p14/european-respiratory-society-ers-2026-international-congress-2026a1000qk0

Mosliciguat Makes Headway Against Pulmonary Hypertension in Interstitial Lung Disease (+++)

https://www.medscape.com/viewarticle/mosliciguat-makes-headway-against-pulmonary-hypertension-2026a1000z23?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 Genetics Starting to Play a Greater Role in Clinical Management of ILD https://www.medscape.com/viewarticle/genetics-starting-play-greater-role-clinical-management-ild-2026a1000zjw?ecd=mkm_ret_261011_mscpmrk_pulm_trending-news_etid8778820&uac=148436CN&impID=8778820 European Respiratory Society (ERS) 2026 International Congress https://www.medscape.com/c25/p14/european-respiratory-society-ers-2026-international-congress-2026a1000qk0

Navigating Myelofibrosis-Associated Anemia Together: Empowering Collaboration and Communication Authors: Francesco Passamonti, MD

https://www.medscape.org/viewarticle/navigating-myelofibrosis-associated-anemia-together-2026a10007ks?page=1&src=mkmcmr_driv_stan_mscpedu_261010-OUS-HONC-navigating-myelofibrosis-associated-anemia-together-2026a10007ks-cta&uac=148436CN

Why Is Gout on the Rise? Kenneth Saag, MD; Hyon K. Choi, MD

https://www.medscape.com/ca8/p04/podcast-gout-s1-ep3-2026a1000qek?ecd=mkm_mscpapp_261010_mscpmrk_podcasts_etid8777174&uac=148436CN&impID=8777174

PMOS: A New Name for a Common Endocrine Disorder Kevin Fernando, MBChB

https://www.medscape.com/p04/pmos-new-name-common-endocrine-disorder-2026a1000zyc?ecd=mkm_mscpapp_261010_mscpmrk_podcasts_etid8777174&uac=148436CN&impID=8777174

Oct 02, 2026 This Week in Cardiology Podcast John M. Mandrola, MD

https://www.medscape.com/viewarticle/1003515#vp_5?ecd=mkm_mscpapp_261010_mscpmrk_podcasts_etid8777174&uac=148436CN&impID=8777174

Common in Clinical Practice: Thyroid Disease and Diabetes Kaniksha Desai, MD; Shashank Joshi, MD

https://www.medscape.com/viewarticle/1003512?ecd=mkm_mscpapp_261010_mscpmrk_podcasts_etid8777174&uac=148436CN&impID=8777174

Challenging the Confines of Risk of Recurrence in High-Risk HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD; Priya Rastogi, MD; Seth Wander, MD, PhD

https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?page=1&src=mkmcmr_driv_stan_mscpedu_261010-OUS-HONC-challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3-cta&uac=148436CN

Medscape Now! Breaking Down Barriers: How Healthcare Teams Can Address Social Determinants to Improve Patient Outcomes Authors: Blessing Ajayi, PA-C

https://www.medscape.org/viewarticle/medscape-now-breaking-down-barriers-how-healthcare-teams-can-2026a1001132?page=1&src=wnl_tpal_261010_mscpedu&uac=148436CN&impID=8782216

Fast Five Quiz: Melanoma Presentation and Diagnosis William D. James, MD

https://reference.medscape.com/viewarticle/fast-five-quiz-melanoma-presentation-and-diagnosis-2026a1001195?ecd=wnl_edit_tpal_etid8783306&uac=148436CN&impID=8783306 Melanoma is a potentially aggressive malignancy of melanocytes with diverse clinical and pathologic presentations. For practicing clinicians, prompt recognition and accurate diagnostic evaluation are essential because the stage at detection strongly influences prognosis and management.

Fad Diets, Fiber, and Food Order: How to Counsel Patients Matthew F. Watto, MD; Paul N. Williams, MD

https://www.medscape.com/viewarticle/fad-diets-fiber-and-food-order-how-counsel-patients-2026a10010t1?ecd=wnl_edit_tpal_etid8783306&uac=148436CN&impID=8783306

Unifying Expertise in IDH-Mutant Glioma Care: A Multidisciplinary Dialogue in the Oncology Team Authors: Shawn Hervey-Jumper, MD; Markus Bredel, MD, PhD; Matthias Preusser, MD

https://www.medscape.org/viewarticle/unifying-expertise-idh-mutant-glioma-care-multidisciplinary-2026a1000myk?page=1&src=mkmcmr_driv_stan_mscpedu_261011-OUS-HONC-unifying-expertise-idh-mutant-glioma-care-multidisciplinary-2026a1000myk-cta&uac=148436CN

The Macroeconomic Impact of Climate Change: Global Versus Local Temperature Get access Arrow Adrien Bilal , Diego R Känzig

The Macroeconomic Impact of Climate Change: Global Versus Local Temperature Get access Arrow Adrien Bilal , Diego R Känzig https://academic.oup.com/qje/article-abstract/141/2/889/8490467?redirectedFrom=fulltext&login=false This article estimates that the macroeconomic damages from climate change are an order of magnitude larger than previously thought. Exploiting natural global temperature variability, we find that 1ºC warming reduces world GDP by over 20% in the long run. Global temperature correlates strongly with extreme climatic events, unlike country-level temperature used in previous work, explaining our larger estimate. We use this evidence to estimate damage functions in a neoclassical growth model. Business-as-usual warming implies a present welfare loss of more than 30%, and a social cost of carbon in excess of $1,200 per ton. These impacts suggest that unilateral decarbonization policy is cost-effective for large countries such as the United States.

Valuing the Global Mortality Consequences of Climate Change Accounting for Adaptation Costs and Benefits* Tamma Carleton , Amir Jina , Michael Delgado , Michael Greenstone , Trevor Houser , Solomon Hsiang , Andrew Hultgren , Robert E Kopp , Kelly E McCusker , Ishan Nath ...

Valuing the Global Mortality Consequences of Climate Change Accounting for Adaptation Costs and Benefits* Tamma Carleton , Amir Jina , Michael Delgado , Michael Greenstone , Trevor Houser , Solomon Hsiang , Andrew Hultgren , Robert E Kopp , Kelly E McCusker , Ishan Nath ... https://academic.oup.com/qje/article/137/4/2037/6571943?login=false Using 40 countries’ subnational data, we estimate age-specific mortality-temperature relationships and extrapolate them to countries without data today and into a future with climate change. We uncover a U-shaped relationship where extre6me cold and hot temperatures increase mortality rates, especially for the elderly. Critically, this relationship is flattened by higher incomes and adaptation to local climate. Using a revealed-preference approach to recover unobserved adaptation costs, we estimate that the mean global increase in mortality risk due to climate change, accounting for adaptation benefits and costs, is valued at roughly 3.2% of global GDP in 2100 under a high-emissions scenario. Notably, today’s cold locations are projected to benefit, while today’s poor and hot locations have large projected damages. Finally, our central estimates indicate that the release of an additional ton of CO2 today will cause mortality-related damages of $36.6 under a high-emissions scenario, with an interquartile range accounting for both econometric and climate uncertainty of [−$7.8, $73.0]. These empirically grounded estimates exceed the previous literature’s estimates by an order of magnitude. Heat, air pollution, and global temperature shocks Patrick Behrer October 07, 2026 This page in: English https://blogs.worldbank.org/en/impactevaluations/heat--air-pollution--and-global-temperature-shocks Developing countries face a host of environmental challenges, but two of the most significant are air pollution and climate change. Wealthy countries face both as well, but the highest levels of air pollution, the fastest growth in pollution, and the least climate-resilient populations are all in low- and middle-income countries (LMICs). Some policies address both problems at once (reducing coal-fired power generation, for example). But win-win solutions do not always exist. Global Temperature and Global Mortality Adrien Bilal, Diego R. Känzig & Krzysztof Lisiecki https://www.nber.org/papers/w35832 This paper documents large indirect mortality impacts of climate change. Exploiting natural global temperature variability, we find that 1°C of warming increases annual mortality by 2.5 deaths per 1,000 individuals, compared to 0.1 deaths per 1,000 due to the associated local heat exposure. Using external estimates of the impact of global income on mortality, we show that the macroeconomic effects of global temperature changes explain two thirds of the gap between these estimates. We use this evidence to estimate damage functions in a neoclassical growth model that links mortality and economic activity and accounts for adaptation to mortality impacts. Mortality contributes $400 per ton of CO₂ to the Social Cost of Carbon, or one quarter of total climate damages. These results suggest that economic adaptation has a double dividend by also reducing climate-related mortality.

FDA Approves Camzyos (Mavacamten) for Obstructive Hypertrophic Cardiomyopathy by Madaline Spencer| Published on: Oct 6, 2026

FDA Approves Camzyos (Mavacamten) for Obstructive Hypertrophic Cardiomyopathy by Madaline Spencer| Published on: Oct 6, 2026 The US Food and Drug Administration (FDA) has approved Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in patients weighing 30 kg (66 lbs) or more. https://checkrare.com/fda-approves-camzyos-mavacamten-for-obstructive-hypertrophic-cardiomyopathy/

Priority Review for Dersimelagon in the Treatment of EPP and XLP

Topline Results From the SANRECO Trial Testing Divesiran in Polycythemia Vera

Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval

A Patient’s Journey With Essential Thrombocythemia and Polycythemia Vera

Plasma Proteomics May Predict Disease Manifestations in ALS by Madaline Spencer| Published on: Oct 9, 2026

Plasma Proteomics May Predict Disease Manifestations in ALS by Madaline Spencer| Published on: Oct 9, 2026 Michael Benatar, MD, PhD, Department of Neurology and ALS Center, University of Miami Miller School of Medicine, discusses the use of plasma proteomics in predicting clinical manifestations of amyotrophic lateral sclerosis (ALS). https://checkrare.com/plasma-proteomics-may-predict-disease-manifestations-in-als/

Most Read Papers - Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_261009

Blood proteins may offer new clues to gut health in coeliac disease

https://www.news-medical.net/news/20261010/Blood-proteins-may-offer-new-clues-to-gut-health-in-coeliac-disease.aspx Coeliac disease is an autoimmune condition in which the immune system reacts adversely to gluten. Eating gluten causes inflammation in the gut, which can damage the intestine and impair its ability to absorb nutrients.

Scientists identify the neuroblastoma cells that signal poor outcomes

https://www.news-medical.net/news/20261010/Scientists-identify-the-neuroblastoma-cells-that-signal-poor-outcomes.aspx Neuroblastoma is the most common solid tumor found outside of the brain in children, yet why some children respond well to treatment while others do not has remained poorly understood. St. Jude Children’s Research Hospital scientists and their collaborators built one of the most comprehensive datasets of neuroblastoma cells to date, using it to define the tumor’s cell types and identify a gene signature marking a malignant cell population tied to poor prognosis. The team also created patient-derived models that capture this population, which older laboratory cell lines had missed. The findings, published today in Cancer Cell, give researchers a new framework and a set of tools to study high-risk neuroblastoma.

Body fat distribution may influence hunger hormones more than daily diet

https://www.news-medical.net/news/20261009/Body-fat-distribution-may-influence-hunger-hormones-more-than-daily-diet.aspx Why do people with different body types respond differently to the same meal? In a recent study published in Nutrients, researchers assessed how dietary intake and body composition affect fasting and postprandial ghrelin levels.

A technology guide to assessing liver safety with microphysiological systems

https://cn-bio.com/resource/a-technology-guide-to-assessing-liver-safety-with-microphysiological-systems/?utm_campaign=263069939-TOX-3rd%20Party%20Marketing%20Activities&utm_source=ppc&utm_medium=AZO-newsletter&utm_content=dili-guide Drug-induced liver injury remains one of the most significant safety challenges in drug development. This technology guide explores how liver microphysiological systems help de-risk safety assessment, investigate DILI mechanisms, and generate human-relevant insight. Includes practical implementation considerations and emerging regulatory perspectives.

Industry Focus eBook - Metabolomics (++...)

https://www.news-medical.net/industry-focus/Industry-Focus-eBook-Metabolomics-1?PreviewCode=dca4c983-8873-4fec-ab90-45a839e974a4&utm_source=azonetwork_newsletter&utm_medium=email&utm_campaign=drug_discovery_newsletter_1_october_2026 Metabolomics is providing increasingly detailed insights into the complex relationship between metabolism, disease, and human health. The latest edition of the Metabolomics Industry Focus eBook explores advances in metabolomics, lipidomics, and multi-omics research, exploring how these approaches help researchers better understand biological processes, identify disease mechanisms, and uncover potential biomarkers. https://www.news-medical.net/medical/ebooks

Ablation Falls Short in Oligometastatic Breast Cancer Trial October 09, 2026

https://www.medscape.com/viewarticle/ablation-falls-short-oligometastatic-breast-cancer-trial-2026a10011zk?src= Adding metastasis-directed ablation to first-line systemic therapy did not improve progression-free or overall survival in patients with oligometastatic breast cancer. Two-year overall survival estimates were 88.4% with systemic therapy alone and 78% with ablation.

HER2-Positive Breast Cancer in 2026: The Treatment Map Is Getting More Complicated

https://www.medscape.com/c99/p10/her2-positive-breast-cancer-2026-treatment-map-getting-more-2026a10011sr?src= Treatment for early HER2-positive breast cancer is moving in two directions. For some patients, the question is how much therapy can safely be stripped away — and the data increasingly support doing so. At the other end of the risk spectrum, new data are supporting treatment escalation for patients with high-risk disease or residual invasive disease after neoadjuvant therapy.

Don’t Wait to Act: Recognizing Refractory HSV and Leveraging New Treatment Pathways Authors: Anum Abbas, MD; Jonathan M. Hand, MD

https://www.medscape.org/viewarticle/dont-wait-act-recognizing-refractory-hsv-and-leveraging-new-2026a10010ym?page=1

Serious disorder may go unnoticed in men who appear physically fit, and more health news (+...)

Men are hiding potentially deadly disorder amid pressure to build the 'perfect' body Sylvester Stallone’s bulimia admission sparks warnings from eating disorder experts Melissa Rudy By Melissa Rudy Fox News Published October 2, 2026 7:00am EDT https://www.foxnews.com/health/men-hiding-potentially-deadly-disorder-amid-pressure-build-perfect-body?lid=j66ov2v2iv9y One type of sleep linked to dramatically lower risk of dementia, Parkinson's and 81 other diseases https://www.foxnews.com/health

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1) https://clinicaltrials.gov/study/NCT03073967?utm_medium=email&utm_source=govdelivery FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus Action FDA has approved Hovilpri (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. Disease or Condition Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are common viral infections that typically cause painful mucocutaneous lesions, or fluid-filled blisters that break open and crust over the infectious site. Once a person has HSV, the infection cannot be cured. The virus can be dormant or can reactivate, leading people to have outbreaks or release contagious viral particles without being symptomatic. There are several FDA-approved antiviral treatments that can help control or improve outbreaks. Patients with compromised immune systems can have more frequent and serious HSV outbreaks that might not respond well to available treatments because their virus is resistant to the medications or they cannot tolerate side effects. Effectiveness The efficacy of Hovilpri was evaluated in a randomized, open-label, comparator-controlled, superiority trial (PRIOH-1 Phase 3 Trial, Part C; NCT 03073967) in immunocompromised participants with mucocutaneous HSV infection who did not respond to treatment with acyclovir, valacyclovir, or famciclovir. Participants received Hovilpri or the trial investigator’s choice of available treatments for up to 28 days until all mucocutaneous lesions healed, which was extended up to 42 days if lesions were improving but not completely healed after 28 days. A total of 101 immunocompromised adults were randomly assigned and treated with Hovilpri or the investigator’s choice of available treatments. Participants had a wide range of immunosuppressive clinical conditions, including one or more of the following: hematologic malignancy/disorder, hematopoietic stem-cell transplantation, HIV infection, autoimmune/inflammatory diseases, non-hematologic malignancies, or solid-organ transplantation. The primary efficacy endpoint was the proportion of participants with all lesions healed during the treatment period up to 28 days. By 28 days, all lesions were healed in 63% of patients receiving Hovilpri, compared with 34% of patients receiving one of the other medications. Safety The most common adverse reaction was headache. See the prescribing information about certain drug interactions with Hovilpri. Designations Hovilpri received priority review for this indication.

Menopause: Three Things You May Not Know David Warmflash, MD (+++++)

Menopause: Three Things You May Not Know David Warmflash, MD https://www.medscape.com/viewarticle/menopause-three-things-you-may-not-know-2026a10011ss?ecd=wnl_edit_tpal_etid8780049&uac=148436CN&impID=8780049 As a clinician, you probably understand the physiology and pathophysiology of menopause quite well. Some, possibly many, of your patients may require active management of menopause: evaluating symptoms, preventive health screenings, monitoring their bone health and cardiovascular risks, lifestyle counseling. But here are three things you may not know about the history of humans dealing with menopause and medicine's efforts to understand the process. High-Dose DHA Fails to Improve Cognitive Decline in Trial https://www.medscape.com/s/viewarticle/high-dose-dha-fails-improve-cognitive-decline-trial-2026a10011s0?ecd=wnl_edit_tpal_etid8780049&uac=148436CN&impID=8780049 Scalding Drinks Increase Esophageal Cancer Risk Benjamin H. Levy, III, MD; Emil Lou, MD, PhD https://www.medscape.com/viewarticle/scalding-drinks-increase-esophageal-cancer-risk-2026a100118p?ecd=wnl_edit_tpal_etid8780049&uac=148436CN&impID=8780049 Are We Overdiagnosing Melanoma? Kate Gerber, MD https://www.medscape.com/viewarticle/are-we-overdiagnosing-melanoma-2026a10010td?ecd=wnl_edit_tpal_etid8780049&uac=148436CN&impID=8780049 SNAP, Crackle, Pop: Cuts Won’t Make America Healthy Again Vanessa M. Oddo, PhD, MPH https://www.medscape.com/viewarticle/snap-crackle-pop-cuts-wont-make-america-healthy-again-2026a10011m4?ecd=wnl_edit_tpal_etid8780049&uac=148436CN&impID=8780049

A Man With Electrical Injury Develops Alveolar Hemorrhage Julia Senn

https://www.medscape.com/viewarticle/man-electrical-injury-develops-alveolar-hemorrhage-2026a10011wu

Are We Overdiagnosing Melanoma? Kate Gerber, MD

https://www.medscape.com/viewarticle/are-we-overdiagnosing-melanoma-2026a10010td?src=

Ovarian Cancer Mortality Risk Drops to Normal at 10 Years

https://www.medscape.com/viewarticle/ovarian-cancer-mortality-risk-drops-normal-10-years-2026a1000y8d?src= Hello. I'm Dr Maurie Markman, from City of Hope. I would like to discuss a very interesting topic and a very interesting analysis. I would suggest that we need more of these types of analyses. The paper I'm describing is entitled "Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis," published in JCO Oncology Advances.

Scalding Drinks Increase Esophageal Cancer Risk (+...)

Oncology Perspective Scalding Drinks Increase Esophageal Cancer Risk Drs Benjamin Levy and Emil Lou discuss new International Journal of Cancer data linking very hot drinks to esophageal cancer risk — and what to tell patients. Medscape Gastroenterology, October 08, 2026 https://www.medscape.com/index/list_13293_0

MHRA Approves New Treatment for Malignant Ascites Dr Sheena Meredith

https://www.medscape.com/viewarticle/mhra-approves-new-treatment-malignant-ascites-2026a10011q2?src= The Medicines and Healthcare products Regulatory Agency (MHRA) has approved catumaxomab (Korjuny, Lindis Biotech) to treat malignant ascites in adults when standard treatment of their cancer is no longer feasible.

Felzartamab Extends PFS in Relapsed Myeloma, but at the Cost of Increased Toxicity October 09, 2026

https://www.medscape.com/viewarticle/felzartamab-extends-pfs-relapsed-myeloma-cost-increased-2026a10011xp?src= Adding felzartamab, a novel anti-CD38 monoclonal antibody, to lenalidomide-dexamethasone significantly extended progression-free survival (PFS) compared with lenalidomide-dexamethasone alone in Chinese patients with relapsed or refractory multiple myeloma, a phase 3 trial found. However, the treatment was associated with substantially greater toxicity, including neutropenia, lymphopenia, and pneumonia.

American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting

https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5

FDA Approves Atezolizumab With Chemo Combo for Colon Cancer Katie Lennon

https://www.medscape.com/viewarticle/fda-approves-atezolizumab-chemo-combo-colon-cancer-2026a10011ya?src= The FDA has approved atezolizumab (Tecentriq, Genentech) with a combination of chemotherapies as adjuvant treatment for adult patients and pediatric patients aged 2 years or older with stage III mismatch repair deficient (dMMR) colon cancer.

Scientists identify new role for tau protein in brain diseases

Scientists identify new role for tau protein in brain diseases At a Glance A study suggests that abnormal tau proteins involved in certain neurodegenerative diseases interact with mitochondria to drive a process called reverse electron transport. Inhibiting this process may represent a new therapeutic strategy for brain diseases linked to abnormal tau. https://www.nih.gov/news-events/nih-research-matters/scientists-identify-new-role-tau-protein-brain-diseases

Estimating cognitive impairment risk, timing

Estimating cognitive impairment risk, timing At a Glance Combining blood p-tau217 levels together with APOE4 gene status improved predictions of dementia risk. The findings may help doctors better assess patients’ risk for cognitive impairment and estimate when symptoms may develop. https://www.nih.gov/news-events/nih-research-matters/estimating-cognitive-impairment-risk-timing

Improving lung cancer detection

Improving lung cancer detection At a Glance Researchers developed a protein-based MRI contrast agent that could detect a common lung cancer in mouse models and determine if it spread to other organs. With further development, the approach could help doctors detect lung cancer earlier and tailor treatment to the needs of each patient. https://www.nih.gov/news-events/nih-research-matters/improving-lung-cancer-detection

Device helps people with paralysis communicate

Device helps people with paralysis communicate At a Glance A brain-computer interface linked to a virtual avatar helped people with paralysis express speech and body language at the same time. Translating neural signals for both types of communication could enable people with paralysis to express themselves more fully. https://www.nih.gov/news-events/nih-research-matters/device-helps-people-paralysis-communicate

When a failed trial isn't a failed drug A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment. Written byBree Foster, PhD

When a failed trial isn't a failed drug A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment. Written byBree Foster, PhD https://www.drugdiscoverynews.com/when-a-failed-trial-isn-t-a-failed-drug-17431?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--mxkzU3Gubg4olGXThSyNhbwo1LkK8D-VbpIDPK_Ce-Gi1oNSKP3mkcGO4UioLOPx_pYHAYAoiRJuqkzK0VmbcE1DOrQ&_hsmi=443231356&utm_content=443231356&utm_source=hs_email When a Phase 3 clinical trial misses its primary endpoint, the outcome is often treated as definitive. The drug failed to demonstrate efficacy, development stops, and the therapy may never be tested again. But a negative trial in a heterogeneous patient population does not necessarily mean that every participant failed to benefit. It may instead mean that any treatment effect was diluted when patients with very different disease biology and treatment responses were analyzed together. That possibility has become increasingly important as drug development moves toward precision medicine. Many diseases once treated as single disorders are now understood to encompass biologically diverse patient populations. But pivotal Phase 3 trials are still generally designed to answer a binary question: does the drug work across the overall study population?

​The Alzheimer's drug working upstream of amyloid New imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity. Written byAndrea Corona

​The Alzheimer's drug working upstream of amyloid New imaging analysis from the Phase 2a trial of a new small molecule drug shows dose-dependent preservation of whole-brain connectivity. Written byAndrea Corona https://www.drugdiscoverynews.com/the-alzheimer-s-drug-working-upstream-of-amyloid-17449?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--U0ZwnxsGXD1zAoxfxwKppQPdlU20Qgw2rMK0k5ZFS-q8JiUwJU2PjTxBfihxC7oNuX8aozXzvC5djG0YGYelklbeqhw&_hsmi=443231356&utm_content=443231356&utm_source=hs_email Most of the recent progress in Alzheimer's disease therapeutics has centered on clearing amyloid from the brain. The approval of lecanemab and donanemab has validated the amyloid hypothesis well enough to change clinical practice, but neither drug stops the disease. They slow it, modestly, in carefully selected patients. The field's attention is increasingly turning to what comes after amyloid accumulation: the cascade of synaptic damage, network disruption, and cognitive decline that amyloid pathology sets in motion but does not entirely account for.

Can 21,000 plasma samples help untangle mixed dementia? Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that mixture and help researchers identify the right patients for future clinical trials. Written byGustav Ceder

Can 21,000 plasma samples help untangle mixed dementia? Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that mixture and help researchers identify the right patients for future clinical trials. Written byGustav Ceder https://www.drugdiscoverynews.com/can-21-000-plasma-samples-help-untangle-mixed-dementia-17578?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9nM2ELZb_5s2du1zQAioZEk384NToF7mOrerO7vkoAew8bppl6VIvKWoWN_4SUej85gWwJ-yMSD5JekWrJVN1yyvoRRg&_hsmi=443231356&utm_content=443231356&utm_source=hs_email A diagnosis of Alzheimer’s disease does not necessarily explain everything happening in a person’s brain. Amyloid plaques accumulate between neurons, while tau tangles form inside them. But these changes can coexist with vascular damage and other abnormal protein deposits. When multiple disease processes contribute to a person’s dementia, the condition is known as mixed dementia. People with similar symptoms may have different combinations of underlying diseases, potentially influencing how they respond to a drug. “Typically, more than just Alzheimer’s disease is contributing to their dementia,” said Sterling Johnson, a dementia researcher at the University of Wisconsin–Madison.

Nobel prize in physiology or medicine awarded for lighting up the field of neuroscience Proteomic studies, billion dollar pharma deals, WHO initiatives, and more led the news this week. Brought to you byDDN editorial team

Nobel prize in physiology or medicine awarded for lighting up the field of neuroscience Proteomic studies, billion dollar pharma deals, WHO initiatives, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/nobel-prize-in-physiology-or-medicine-awarded-for-lighting-up-the-field-of-neuroscience-17580 The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University, and Georg Nagel of the University of Würzburg “for their discoveries concerning light-gated ion channels and optogenetics,” according to the press release. In the early 2000s, Hegemann and Nagel discovered the channelrhodopsin protein in a single-cell alga, which is activated by blue light. Then, in 2005, Deisseroth published work showing that inserting the channelrhodopsin gene into the brain cells of rats also activated these cells, triggering action potentials. The breakthrough offered neuroscientists an unprecedented view of the intricate and precise behavior of neural circuits. In the statement from the Nobel Assembly at Karolinska Institute, the team wrote, “The Laureates have laid the foundation of a new era in neuroscience.” – Allison Whitten

Testosterone Use in Menopausal Women: Watch the Recording from FDA Public Workshop “Testosterone Use in Menopausal Women”

On September 17, 2026, the FDA Office of Women’s Health (OWH) and Center for Drug Evaluation and Research (CDER) hosted a public workshop on Testosterone Use in Menopausal Women. The workshop examined the current scientific evidence and critical knowledge gaps in this area to help inform future research and potential drug development. Missed the workshop? Watch the full recording on FDA’s YouTube channel to hear the scientific discussion and key perspectives shared during the meeting. In addition to the workshop, the FDA also opened a docket to allow for submission of broad, public comments on the risks and benefits related to testosterone use in menopausal women.The docket will be open for public comments for 60 days. Comments must be received no later than 11:59 p.m. ET on October 19, 2026, to be considered. Visit Regulations.gov for comment submission requirements. For more information about the workshop, including the agenda and speaker bios, visit: FDA Public Meeting: Testosterone Use In Menopausal Women - 09/17/2026 | FDA.   https://www.fda.gov/consumers/womens-health-events/fda-public-meeting-testosterone-use-menopausal-women-09172026?utm_medium=email&utm_source=govdelivery

NIST Study Shows How the Toxic Substances Mixed Into Fentanyl Vary Across the U.S. and Change Over Time October 8, 2026

https://www.nist.gov/news-events/news/2026/10/nist-study-shows-how-toxic-substances-mixed-fentanyl-vary-across-us-and Public health officials and law enforcement agents are facing a growing challenge in combating the fentanyl epidemic: They lack detailed and timely information on the harmful and potentially deadly substances, including anesthetics, industrial chemicals, veterinary sedatives and other adulterants, that drug suppliers increasingly mix into the illicit fentanyl supply. Now, a new study from the National Institute of Standards and Technology (NIST) reveals how the prevalence of these adulterants changes over time and across different regions of the country. NIST chemist Edward Sisco and his colleagues base their findings, reported in Drug Testing and Analysis, on an analysis of 4,563 samples of drug residues collected nationwide between January 2024 and June 2026. The team relied on a technology that identifies trace amounts of unknown compounds within seconds.

Taking on the RAS Challenge October 8, 2026, by Linda Wang

https://www.cancer.gov/news-events/cancer-currents-blog/2026/taking-on-ras-challenge?cid=eb_govdel For decades, RAS proteins were considered nearly impossible to target with drugs. NCI-supported basic research and the RAS Initiative helped lay the groundwork for new RAS inhibitors that are now benefiting patients and advancing through clinical trials.

Recommended CME For You (+++++ +++++)

Targeted Therapies for NSCLC: Where Are We Today? CME https://www.medscape.org/viewarticle/1002896?src=mkmcmr_driv_invit_mscpedu&uac=148436CN PTEN Deficiency in Prostate Cancer: Biology, Prognosis, and Therapeutic Relevance CME https://www.medscape.org/viewarticle/pten-deficiency-prostate-cancer-biology-prognosis-and-2025a1000rqh?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN NF-1 Associated Plexiform Neurofibromas in Adults: Which Patients Could Benefit From Emerging Systemic Therapies? CME https://www.medscape.org/viewarticle/1003044?src=mkmcmr_driv_invit_mscpedu&uac=148436CN High-Risk HR-Positive, HER2-Negative Early Breast Cancer: Latest Updates From the European Oncology Congress CME https://www.medscape.org/viewarticle/high-risk-hr-positive-her2-negative-early-breast-cancer-2025a1000udm?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Expanding the Frontiers of HER2-Targeted Therapy in Gynecologic Cancers CME https://www.medscape.org/viewarticle/expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC CME https://www.medscape.org/viewarticle/conference-insights-breaking-developments-alk-positive-nsclc-2025a1000vwn?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Latest Advances in mHSPC: An Update From Berlin 2025 CME https://www.medscape.org/viewarticle/latest-advances-mhspc-update-berlin-2025-2025a1000vlk?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Pediatric Low-Grade Glioma With BRAF Alterations: Stories, Science, and Strategies CME https://www.medscape.org/viewarticle/pediatric-low-grade-glioma-braf-alterations-stories-science-2025a1000x3w?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Tenosynovial Giant Cell Tumor in Focus: Quickfire Insights From Multidisciplinary Experts CME https://www.medscape.org/viewarticle/tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Shaping the Future of Precision Oncology: Biomarker-Driven Care for Tumor-Agnostic Therapies CME https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN

Clean air is lung care The Lancet Child & Adolescent Health (++... ++)

Clean air is lung care The Lancet Child & Adolescent Health https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00246-4/fulltext?dgcid=raven_jbs_etoc_email Nov 2026 Volume 10Number 11p777-846 https://www.thelancet.com/journals/lanchi/issue/vol10no11/PIIS2352-4642(26)X2009-0 Injury burden among adolescents and young adults aged 10–24 years in the Arab region, 1990–2023: a systematic analysis of the Global Burden of Disease Study 2023 Dian Kusuma, DSca,b ∙ Abrari Noor Hasmi, PhDa ∙ Ankita Shukla, PhDc ∙ Prof Rebecca Ivers, PhDd ∙ Prof Ali H Mokdad, PhDe ∙ Prof Basema Saddik, PhD https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00168-9/abstract?dgcid=raven_jbs_etoc_feature_lanchi Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial Daniel J Kapelus, MSca ∙ Courtney P Olwagen, PhDa ∙ Alane Izu, PhDa ∙ Heena Ranchod, PhDb,c ∙ Christian K Mukendi, MSca ∙ Eleonora A M L Mutsaerts, PhDa,g ∙ et al. https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00164-1/abstract?dgcid=raven_jbs_etoc_feature_lanchi

Rural health care: from policy ambition to local reality The Lancet Primary Care (++... ++)

Rural health care: from policy ambition to local reality The Lancet Primary Care https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00118-4/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 2Number 9 https://www.thelancet.com/journals/lanprc/issue/vol2no9/PIIS3050-5143(26)X2009-X Prescribing cascades, associated patient characteristics, and health-care utilisation in older community-dwelling adults in Ireland: a retrospective, observational cohort study Steven Gilmore, MPHa Send email to sgilmore@ucc.ie ∙ Ann Sinéad Doherty, PhDb ∙ Frank Moriarty, PhDb ∙ Fiona Boland, PhDc ∙ Ryan Muddiman, PhDb ∙ Prof Tom Fahey, MDd ∙ et al. https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00102-0/fulltext?dgcid=raven_jbs_etoc_feature_lanprc Effectiveness of the Responses to Illness Severity Quantification (RISQ) system versus standardised malnutrition treatment on mortality in acutely malnourished children treated in a community-based nutrition programme in Ngouri, Chad (CRIMSON): a multicentre, cluster-randomised trial Nancy M Dale, PhDa,b,c,d ∙ Youssouf Djidita Hagre, MMede ∙ Djamnoné L Debtanné, MDf ∙ Difo Saha Mermoz, MDf ∙ Boubacar Harouna, RNf ∙ Innocent Golnodji, RNf ∙ et al. https://www.thelancet.com/journals/lanprc/article/PIIS3050-5143(26)00104-4/fulltext?dgcid=raven_jbs_etoc_feature_lanprc

The metaphysics of fine-tuning the universe By Bioethics Observatory

https://bioethicsobservatory.org/2026/09/the-metaphysics-of-fine-tuning-the-universe/49027/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet The metaphysics of fine-tuning the universe By Bioethics Observatory Published On: September 24th, 2026 Categories: Bioethics, BIOETHICS NEWS, Origin of the universe and life, SPECIAL REPORTS Why do the fundamental laws and constants of the universe possess precisely the values that allow for the existence of stars, planets, complex chemistry, and, ultimately, life? The so-called “fine-tuning of the universe” is one of the great questions that contemporary cosmology has yet to solve: slight variations in certain physical parameters would have produced a radically different cosmos, incompatible with life. From Fred Hoyle’s astonishing prediction of carbon formation to current multiverse hypotheses, science has sought to explain this extraordinary precision. Yet this issue transcends the limits of physics and opens an inevitably metaphysical question: is fine-tuning a product of chance, a consequence of still unknown laws, or an indication of purpose and intelligence?

Synthetic cells and the creation of life: scientific advances, biological limits, and bioethical challenges By Bioethics Observatory

Synthetic cells and the creation of life: scientific advances, biological limits, and bioethical challenges By Bioethics Observatory Published On: July 31st, 2026 Categories: Bioethics, BIOETHICS NEWS, SPECIAL REPORTS, Synthetic Biology Is it possible to create life in a laboratory? The most recent advances in synthetic biology have made it possible to develop artificial cells with some of the functions typical of living organisms, rekindling the debate over the boundaries between the natural and the designed. This article analyzes the true scientific scope of these achievements, their potential applications, and the important bioethical questions they raise about the nature of life and human responsibility. https://bioethicsobservatory.org/2026/07/synthetic-cells-and-the-creation-of-life-scientific-advances-biological-limits-and-bioethical-challenges/48945/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Palliative medicine and its ethical commitment to care for people By Bioethics Observatory

Palliative medicine and its ethical commitment to care for people By Bioethics Observatory Published On: October 8th, 2026 Categories: Bioethics, BIOETHICS NEWS, Palliative Care, SPECIAL REPORTS Palliative Care is the ethical commitment of a society that is sensitive to the suffering of its citizens. When medicine has failed to prevent or cure a disease, the physician must commit to caring for and supporting the person suffering from the disease in order to alleviate their suffering. It is then that we must adopt an ethical perspective on care, guided by the five ethical imperatives of palliative care: https://bioethicsobservatory.org/2026/10/palliative-medicine-and-its-ethical-commitment-to-care-for-people/49070/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet

Mifepristone in emergency contraception: a new threat to the embryo By Bioethics Observatory

https://bioethicsobservatory.org/2026/10/mifepristone-in-emergency-contraception-a-new-threat-to-the-embryo/49045/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet Mifepristone in emergency contraception: a new threat to the embryo By Bioethics Observatory Published On: October 2nd, 2026 Categories: Bioethics, BIOETHICS NEWS, Emergency Contraception, Regulation of human reproduction. Contraceptives, SPECIAL REPORTS A recent meta-analysis evaluates the efficacy of low-dose mifepristone as an emergency contraceptive compared to other interventions. Beyond its effectiveness in reducing pregnancy rates, its mechanism of action and ability to interfere with endometrial receptivity has reignited the debate surrounding its bioethical implications and the information women receive about its possible effects.

Are You Living with Breast Cancer? Palliative Care Can Help (+ + + + +...x5)

October is Breast Cancer Awareness Month. If you or a loved one has received a breast cancer diagnosis, you know how overwhelming it can feel. You may have gone from thinking everything was okay to suddenly needing to decide about surgery and starting treatments such as radiation or chemotherapy. On top of this, you may experience symptoms such as pain, nausea, anxiety, and fatigue. Combined, this may all feel very stressful and overwhelming. You’re not alone. Palliative care can help. Explore this selection of blogs with information, resources, and support: Are You Living with Breast Cancer? Palliative Care Can Help https://getpalliativecare.org/are-you-living-with-breast-cancer-palliative-care-can-help2022/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 If you or a loved one have received a breast cancer diagnosis, you know that it can be scary. You may have gone from thinking everything was okay to suddenly needing to decide about surgery and starting treatments such as radiation or chemotherapy. On top of this, you may experience symptoms such as pain, nausea, anxiety, and fatigue. Combined, this may all feel very stressful and overwhelming. You’re not alone. Palliative care can help. Living With Metastatic Breast Cancer? Here’s How Palliative Care Can Help https://getpalliativecare.org/living-with-metastatic-breast-cancer-heres-how-palliative-care-can-help/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 How Palliative Care Helps with Body Image Concerns from Breast Cancer → https://getpalliativecare.org/how-palliative-care-helps-with-body-image-concerns-from-breast-cancer/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 Managing Breast Cancer Symptoms – How Palliative Care Helps → https://getpalliativecare.org/managing-breast-cancer-symptoms-how-palliative-care-helps/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 Palliative Care Provider Directory https://getpalliativecare.org/provider-directory/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 Handout for Patients and Families https://getpalliativecare.org/handouts-for-patients-and-families/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 Articles & Stories https://getpalliativecare.org/articles/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050 Disease Types and Palliative Care https://getpalliativecare.org/whatis/disease-types/?utm_source=Get+Palliative+Care&utm_campaign=b6f3c86190-GPC+-+Breast+Cancer+Month+%2F+10.07.26&utm_medium=email&utm_term=0_4ef32a103e-b6f3c86190-378264050